| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.2174/1389450053765905 |
| P698 | PubMed publication ID | 15857292 |
| P50 | author | Michele Caraglia | Q38321049 |
| Alfredo Budillon | Q40122753 | ||
| Elena Di Gennaro | Q57061563 | ||
| Francesca Bruzzese | Q63737239 | ||
| P2093 | author name string | Caraglia M | |
| Budillon A | |||
| Bruzzese F | |||
| Di Gennaro E | |||
| P433 | issue | 3 | |
| P304 | page(s) | 337-351 | |
| P577 | publication date | 2005-05-01 | |
| P1433 | published in | Current Drug Targets | Q15724627 |
| P1476 | title | Multiple-target drugs: inhibitors of heat shock protein 90 and of histone deacetylase | |
| P478 | volume | 6 |
| Q33322388 | A global view of drug-therapy interactions |
| Q29616624 | Anticancer activities of histone deacetylase inhibitors |
| Q37234005 | Chemical and pathway proteomics: powerful tools for oncology drug discovery and personalized health care. |
| Q99711278 | Curcumin, a Multi-Ion Channel Blocker That Preferentially Blocks Late Na+ Current and Prevents I/R-Induced Arrhythmias |
| Q38045433 | Current treatment of cutaneous squamous cancer and molecular strategies for its sensitization to new target-based drugs. |
| Q40715421 | DTNQ-Pro, a Mimetic Dipeptide, Sensitizes Human Colon Cancer Cells to 5-Fluorouracil Treatment |
| Q38838643 | Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors |
| Q36974707 | Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents |
| Q37284812 | Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors |
| Q39659383 | FK228 induces mitotic catastrophe in A549 cells by mistargeting chromosomal passenger complex localization through changing centromeric H3K9 hypoacetylation |
| Q40331568 | First "hybrid" ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated fatty acid-derived CB2-selective ligands |
| Q36802594 | Focus on acetylation: the role of histone deacetylase inhibitors in cancer therapy and beyond |
| Q39527047 | HDAC inhibitor vorinostat enhances the antitumor effect of gefitinib in squamous cell carcinoma of head and neck by modulating ErbB receptor expression and reverting EMT. |
| Q34805096 | Histone deacetylase inhibitor treatment dramatically reduces cholesterol accumulation in Niemann-Pick type C1 mutant human fibroblasts |
| Q36177918 | Inhibition of histone deacetylase for the treatment of biliary tract cancer: a new effective pharmacological approach |
| Q28272747 | Mechanisms of disease: the role of heat-shock protein 90 in genitourinary malignancy |
| Q39352144 | Pharmacological inhibition of HSP90 and ras activity as a new strategy in the treatment of HNSCC. |
| Q33962243 | Proteomic analysis identifies differentially expressed proteins after HDAC vorinostat and EGFR inhibitor gefitinib treatments in Hep-2 cancer cells. |
| Q36559414 | Raf kinases: oncogenesis and drug discovery |
| Q36546425 | The novel HSP90 inhibitor AT13387 potentiates radiation effects in squamous cell carcinoma and adenocarcinoma cells |
| Q39268578 | Tissue transglutaminase (TG2) is involved in the resistance of cancer cells to the histone deacetylase (HDAC) inhibitor vorinostat. |
| Q34363544 | Vorinostat synergises with capecitabine through upregulation of thymidine phosphorylase. |
Search more.